CHANNEL THERAPEUTICS CORP(NYSEARCA:CHRO) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to CHRO. CHRO was compared to 571 industry peers in the Biotechnology industry. While CHRO seems to be doing ok healthwise, there are quite some concerns on its profitability. CHRO does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

CHRO had negative earnings in the past year.

CHRO had a negative operating cash flow in the past year.

1.2 Ratios

CHRO's Return On Assets of -222.66% is on the low side compared to the rest of the industry. CHRO is outperformed by 91.47% of its industry peers.

The Return On Equity of CHRO (-794.30%) is worse than 83.13% of its industry peers.

		Industry Rank	Sector Rank
ROA	-222.66%
ROE	-794.3%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CHRO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, CHRO has about the same amount of shares outstanding.

Compared to 1 year ago, CHRO has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -9.67, we must say that CHRO is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of CHRO (-9.67) is worse than 72.65% of its industry peers.

CHRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-9.67

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.39 indicates that CHRO should not have too much problems paying its short term obligations.

With a Current ratio value of 1.39, CHRO is not doing good in the industry: 83.30% of the companies in the same industry are doing better.

A Quick Ratio of 1.39 indicates that CHRO should not have too much problems paying its short term obligations.

The Quick ratio of CHRO (1.39) is worse than 82.59% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.39
Quick Ratio	1.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CHRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -203.01%.

EPS 1Y (TTM)-203.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-221.31%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.17% on average over the next years.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-3.62%

EPS Next 2Y5.98%

EPS Next 3Y5.17%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRO. In the last year negative earnings were reported.

Also next year CHRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y5.98%

EPS Next 3Y5.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CHRO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CHANNEL THERAPEUTICS CORP

NYSEARCA:CHRO (2/21/2025, 8:08:47 PM)

After market: 1.74 +0.06 (+3.57%)

1.68

+0.05 (+3.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner Change-70.2%

Ins OwnersN/A

Ins Owner Change0%

Market Cap10.13M

Analysts82.86

Price Target8.67 (416.07%)

Short Float %12.89%

Short Ratio0.09

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	8.96
P/tB	8.96
EV/EBITDA	N/A

EPS(TTM)-1.67

EYN/A

EPS(NY)-1.12

Fwd EYN/A

FCF(TTM)-0.46

FCFYN/A

OCF(TTM)-0.46

OCFYN/A

SpS0

BVpS0.19

TBVpS0.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-222.66%
ROE	-794.3%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.39
Quick Ratio	1.39
Altman-Z	-9.67

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-203.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-221.31%

EPS Next Y-3.62%

EPS Next 2Y5.98%

EPS Next 3Y5.17%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-167.63%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y37.4%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y37.4%

OCF growth 3YN/A

OCF growth 5YN/A

CHANNEL THERAPEUTICS CORP (CHRO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens